EPISODE · May 27, 2014 · 8 MIN
Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab
from Journal of Clinical Oncology (JCO) Podcast
The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.
NOW PLAYING
Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m